Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melavenze is a pharmaceutical product marketed by Makshi Healthcare, typically used in the management of gastrointestinal disorders. While specific formulation details for this brand are limited in public clinical databases, it is categorized by the distributor under gastrointestinal (GI) treatments. In the Indian pharmaceutical market, brands with similar nomenclature often contain Mebeverine, an antispasmodic medication that works by relaxing the smooth muscles of the gastrointestinal tract without affecting normal gut motility. It is primarily indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and related abdominal cramps. Makshi Healthcare operates as a pharmaceutical marketing and distribution company, providing branded generic versions of established therapeutic agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Melavenze.